Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 9
1990 47
1991 42
1992 31
1993 39
1994 46
1995 28
1996 39
1997 32
1998 34
1999 24
2000 48
2001 30
2002 25
2003 24
2004 32
2005 37
2006 44
2007 30
2008 41
2009 37
2010 39
2011 43
2012 43
2013 60
2014 45
2015 37
2016 30
2017 26
2018 17
2019 13
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,025 results
Results by year
Filters applied: . Clear all
Page 1
Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope.
Dorgham K, Pietrancosta N, Affoune A, Lucar O, Bouceba T, Chardonnet S, Pionneau C, Piesse C, Sterlin D, Guardado-Calvo P, Karoyan P, Debré P, Gorochov G, Vieillard V. Dorgham K, et al. J Immunol Res. 2019 Mar 24;2019:9804584. doi: 10.1155/2019/9804584. eCollection 2019. J Immunol Res. 2019. PMID: 31019982 Free PMC article.
HIV-1 vaccine design through minimizing envelope metastability.
He L, Kumar S, Allen JD, Huang D, Lin X, Mann CJ, Saye-Francisco KL, Copps J, Sarkar A, Blizard GS, Ozorowski G, Sok D, Crispin M, Ward AB, Nemazee D, Burton DR, Wilson IA, Zhu J. He L, et al. Sci Adv. 2018 Nov 21;4(11):eaau6769. doi: 10.1126/sciadv.aau6769. eCollection 2018 Nov. Sci Adv. 2018. PMID: 30474059 Free PMC article.
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques.
Han Q, Williams WB, Saunders KO, Seaton KE, Wiehe KJ, Vandergrift N, Von Holle TA, Trama AM, Parks RJ, Luo K, Gurley TC, Kepler TB, Marshall DJ, Montefiori DC, Sutherland LL, Alam MS, Whitesides JF, Bowman CM, Permar SR, Graham BS, Mascola JR, Seed PC, Van Rompay KKA, Tomaras GD, Moody MA, Haynes BF. Han Q, et al. J Virol. 2017 Oct 13;91(21):e00923-17. doi: 10.1128/JVI.00923-17. Print 2017 Nov 1. J Virol. 2017. PMID: 28794027 Free PMC article.
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.
Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. Huang J, et al. Nature. 2012 Nov 15;491(7424):406-12. doi: 10.1038/nature11544. Epub 2012 Sep 18. Nature. 2012. PMID: 23151583 Free PMC article.
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.
Trama AM, Moody MA, Alam SM, Jaeger FH, Lockwood B, Parks R, Lloyd KE, Stolarchuk C, Scearce R, Foulger A, Marshall DJ, Whitesides JF, Jeffries TL Jr, Wiehe K, Morris L, Lambson B, Soderberg K, Hwang KK, Tomaras GD, Vandergrift N, Jackson KJL, Roskin KM, Boyd SD, Kepler TB, Liao HX, Haynes BF. Trama AM, et al. Cell Host Microbe. 2014 Aug 13;16(2):215-226. doi: 10.1016/j.chom.2014.07.003. Cell Host Microbe. 2014. PMID: 25121750 Free PMC article.
Identification of HIV gp41-specific antibodies that mediate killing of infected cells.
Williams KL, Stumpf M, Naiman NE, Ding S, Garrett M, Gobillot T, Vézina D, Dusenbury K, Ramadoss NS, Basom R, Kim PS, Finzi A, Overbaugh J. Williams KL, et al. PLoS Pathog. 2019 Feb 19;15(2):e1007572. doi: 10.1371/journal.ppat.1007572. eCollection 2019 Feb. PLoS Pathog. 2019. PMID: 30779811 Free PMC article.
Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens.
Dennison SM, Anasti K, Scearce RM, Sutherland L, Parks R, Xia SM, Liao HX, Gorny MK, Zolla-Pazner S, Haynes BF, Alam SM. Dennison SM, et al. J Virol. 2011 Feb;85(3):1340-7. doi: 10.1128/JVI.01680-10. Epub 2010 Nov 24. J Virol. 2011. PMID: 21106741 Free PMC article.
[Expression of recombinant HIV-1 envelope glycoprotein gp41].
Teng Z, Li D, Gao L. Teng Z, et al. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1999 Jun 30;13(2):113-6. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1999. PMID: 12569773 Chinese.
1,025 results
Jump to page
Feedback